UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                        Date of Report: February 12, 2020

                       PURE HARVEST CANNABIS GROUP, INC.
                  --------------------------------------------
                (Name of registrant as specified in its charter)

      Colorado                 333-212055                    71-0942431
---------------------     ------------------     ------------------------------
State of Incorporation    Commission File No.    IRS Employer Identification No.

                          2401 E. 2nd Avenue, Suite 600
                                Denver, CO 80206
                           --------------------------
                     Address of principal executive offices

                                 (800) 924-3716
                              --------------------
                      Telephone number, including area code

           Former name or former address if changed since last report

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications  pursuant to Rule 425 under the Securities Act
   (17 CFR 230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
   (17 CFR 240.14a-12)

[ ] Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant to Rule  13e-14(c)  under the
    Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol   Name of each exchange on which registered
-------------------   --------------   -----------------------------------------
       None                N/A                         N/A

Indicate by check mark whether the  Registrant is an emerging  growth company as
defined in Rule 405 of the  Securities  Act of 1933 (230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).

      Emerging Growth Company [x]

If an emerging  growth  company,  indicate by check mark if the  Registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial  accounting  standards provided pursuant to Section 13a of the
Exchange Act. [x]



<PAGE>


Item 8.01   Other Events

     On February 12, 2020, the Company entered into an Operating  Agreement with
Dr. James Rouse, N.M.D.  regarding the ownership,  operation,  and management of
Love Pharm,  LLC. Love Pharm was organized to formulate,  develop,  manufacture,
and  brand  hemp/CBD  products  for sale and  distribution  as well as to form a
multi-channel  media  platform for public and patient  education  regarding  the
endocannabinoid  system  utilizing  Dr.  Rouse's  name,  public  image  and  his
extensive experience and expertise in medicine and  entrepreneurship.  Under the
Operating  Agreement  between the Company and Dr. Rouse, the Company owns 51% of
Love Pharm and has a right of first  refusal to purchase  the  remaining  49% of
Love  Pharm  from  Dr.  Rouse.  Additionally,  Dr.  Rouse  will be  added to the
Company's Advisory Board as the Health,  Wellness & Lifestyle Advisor. Dr. Rouse
will receive 100,000 shares of the Company's common stock for services  provided
to the  Company.  As of May 18,  2020,  Love Pharm is in the  process of product
creation and had not generated any revenue.


                                       2
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

May 18, 2020.

                                    PURE HARVEST CANNABIS GROUP, INC.


                                    By: /s/ Matthew Gregarek
                                        --------------------------------
                                        Matthew Gregarek
                                        Chief Executive Officer











                                       3
[{"type": "8-K", "sequence": "1", "filename": "form8k801luvpharm5-20.txt", "description": "8-K RE LOVE PHARM AGREE", "secsgml_size_bytes": 4468}]
{"company-data": {"conformed-name": "Pure Harvest Cannabis Group, Inc.", "cik": "0001351573", "assigned-sic": "2080", "irs-number": "710952431", "state-of-incorporation": "CO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-212055", "film-number": "20890967"}, "business-address": {"street1": "1624 N. WASHINGTON ST.", "city": "DENVER", "state": "CO", "zip": "80203", "phone": "(800) 560-5148"}, "mail-address": {"street1": "1624 N. WASHINGTON ST.", "city": "DENVER", "state": "CO", "zip": "80203"}, "former-company": [{"former-conformed-name": "Pocket Shot Co", "date-changed": "20160311"}, {"former-conformed-name": "Pocket Shot co", "date-changed": "20060131"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                        Date of Report: February 12, 2020

                       PURE HARVEST CANNABIS GROUP, INC.
                  --------------------------------------------
                (Name of registrant as specified in its charter)

      Colorado                 333-212055                    71-0942431
---------------------     ------------------     ------------------------------
State of Incorporation    Commission File No.    IRS Employer Identification No.

                          2401 E. 2nd Avenue, Suite 600
                                Denver, CO 80206
                           --------------------------
                     Address of principal executive offices

                                 (800) 924-3716
                              --------------------
                      Telephone number, including area code

           Former name or former address if changed since last report

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications  pursuant to Rule 425 under the Securities Act
   (17 CFR 230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
   (17 CFR 240.14a-12)

[ ] Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant to Rule  13e-14(c)  under the
    Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol   Name of each exchange on which registered
-------------------   --------------   -----------------------------------------
       None                N/A                         N/A

Indicate by check mark whether the  Registrant is an emerging  growth company as
defined in Rule 405 of the  Securities  Act of 1933 (230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).

      Emerging Growth Company [x]

If an emerging  growth  company,  indicate by check mark if the  Registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial  accounting  standards provided pursuant to Section 13a of the
Exchange Act. [x]
Item 8.01   Other Events

     On February 12, 2020, the Company entered into an Operating  Agreement with
Dr. James Rouse, N.M.D.  regarding the ownership,  operation,  and management of
Love Pharm,  LLC. Love Pharm was organized to formulate,  develop,  manufacture,
and  brand  hemp/CBD  products  for sale and  distribution  as well as to form a
multi-channel  media  platform for public and patient  education  regarding  the
endocannabinoid  system  utilizing  Dr.  Rouse's  name,  public  image  and  his
extensive experience and expertise in medicine and  entrepreneurship.  Under the
Operating  Agreement  between the Company and Dr. Rouse, the Company owns 51% of
Love Pharm and has a right of first  refusal to purchase  the  remaining  49% of
Love  Pharm  from  Dr.  Rouse.  Additionally,  Dr.  Rouse  will be  added to the
Company's Advisory Board as the Health,  Wellness & Lifestyle Advisor. Dr. Rouse
will receive 100,000 shares of the Company's common stock for services  provided
to the  Company.  As of May 18,  2020,  Love Pharm is in the  process of product
creation and had not generated any revenue.

                                       2
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

May 18, 2020.

                                    PURE HARVEST CANNABIS GROUP, INC.

                                    By: /s/ Matthew Gregarek
                                        --------------------------------
                                        Matthew Gregarek
                                        Chief Executive Officer

                                       3